Log in

Relevant bibliographies by topics / Median combination / Journal articles

To see the other types of publications on this topic, follow the link: Median combination.

Journal articles on the topic 'Median combination'

Author: Grafiati

Published: 2 June 2025

Last updated: 19 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Median combination.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Kundu, A., and J. Zhou. "Combination median filter." IEEE Transactions on Image Processing 1, no. 3 (1992): 422–29. http://dx.doi.org/10.1109/83.148615.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Natsis, Konstantinos, George Paraskevas, and Maria Tzika. "Five Roots Pattern of Median Nerve Formation." Acta Medica (Hradec Kralove, Czech Republic) 59, no. 1 (2016): 26–28. http://dx.doi.org/10.14712/18059694.2016.52.

Full text

Abstract:

An unusual combination of median nerve’s variations has been encountered in a male cadaver during routine educational dissection. In particular, the median nerve was formed by five roots; three roots originated from the lateral cord of the brachial plexus joined individually the median nerve’s medial root. The latter (fourth) root was united with the lateral (fifth) root of the median nerve forming the median nerve distally in the upper arm and not the axilla as usually. In addition, the median nerve was situated medial to the brachial artery. We review comprehensively the relevant variants, t

APA, Harvard, Vancouver, ISO, and other styles

3

Parry, ArshedH, HaseebA Wani, and FerozeA Shaheen. "Fibrolipomatous Hamartoma of Median and Ulnar Nerve: A Rare Combination." Neurology India 69, no. 1 (2021): 234. http://dx.doi.org/10.4103/0028-3886.310107.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Rakheja, Pankaj, and Rekha Vig. "Image Denoising using Combination of Median Filtering and Wavelet Transform." International Journal of Computer Applications 141, no. 9 (2016): 31–35. http://dx.doi.org/10.5120/ijca2016909803.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Pfaffenrath, V., U. Kellhammer та W. Pöllmann. "Combination Headache: Practical Experience with a Combination of a β-Blocker and an Antidepressive". Cephalalgia 6, № 5_suppl (1986): 25–32. http://dx.doi.org/10.1177/03331024860060s503.

Full text

Abstract:

In the prophylaxis of migraine β-blockers are commonly used. In the therapy of tension headache (TH) the use of tricyclic antidepressives is widespread. Therefore, from a rational point of view, one should combine an antidepressive and a β-blocker in the treatment of combination headache (CH), in which patients have both migraine and TH. In an open uncontrolled study, 61 patients with CH received a combination of an antidepressive (amitriptyline or amitriptyline- N-oxide and a β-blocker (propranolol or metoprolol) for at least 3 months. The 61 patients kept a diary in which they recorded frequ

APA, Harvard, Vancouver, ISO, and other styles

6

Cocconi, G., M. Bella, S. Zironi, et al. "Fluorouracil, doxorubicin, and mitomycin combination versus PELF chemotherapy in advanced gastric cancer: a prospective randomized trial of the Italian Oncology Group for Clinical Research." Journal of Clinical Oncology 12, no. 12 (1994): 2687–93. http://dx.doi.org/10.1200/jco.1994.12.12.2687.

Full text

Abstract:

PURPOSE The combination of cisplatin, epirubicin, and leucovorin preceding fluorouracil (PELF) includes three novel agents compared with the standard combination of fluorouracil, doxorubicin, and mitomycin (FAM) in the treatment of advanced gastric carcinoma. We report the results of a prospective randomized comparison of the two combinations in previously untreated patients. PATIENTS AND METHODS One hundred thirty assessable patients were entered onto the trial; 52 received FAM and 85 PELF. A 1:2 unbalanced randomization in favor of the experimental treatment was chosen. Approximately 90% of

APA, Harvard, Vancouver, ISO, and other styles

7

Gies, Anton, Katarina Cuk, Petra Schrotz-King, and Hermann Brenner. "Combination of Different Fecal Immunochemical Tests in Colorectal Cancer Screening: Any Gain in Diagnostic Performance?" Cancers 11, no. 1 (2019): 120. http://dx.doi.org/10.3390/cancers11010120.

Full text

Abstract:

A variety of fecal immunochemical tests (FITs) are used for colorectal cancer screening. FIT performance could be improved further. It is unclear, whether the combination of different FITs with different analytical characteristics (such as, different antibodies for the detection of fecal hemoglobin) can yield a better diagnostic performance. Fecal samples were obtained from 2042 participants of screening colonoscopy. All participants with advanced neoplasm (AN, colorectal cancer (n = 16) or advanced adenoma (n = 200)) and 300 randomly selected participants without AN were included. Nine quanti

APA, Harvard, Vancouver, ISO, and other styles

8

Mazur, Natalia, Rik Osinga, and Steven Lo. "Split median superficial sural artery perforator (MSSAP) flap and medial sural artery perforator (MSAP) flap for posterior thigh sarcoma reconstruction." BMJ Case Reports 13, no. 2 (2020): e233352. http://dx.doi.org/10.1136/bcr-2019-233352.

Full text

Abstract:

Reconstruction of composite defects of the posterior thigh and knee is challenging. Pedicled medial gastrocnemius flaps are the traditional reconstructive approach, but late contractures related to skin grafted muscle may affect knee function. More recently, the medial sural artery perforator (MSAP) flap has been described for such defects, although may necessitate skin grafting of the donor site. To minimise the drawbacks with these options, we describe a combination of a median superficial sural artery perforator (MSSAP) flap and MSAP flap. This allows both tension free closure of the donor

APA, Harvard, Vancouver, ISO, and other styles

9

Dong, Jing, Zhi Chai, and Ke Wen Xia. "A Combination Approach to Noise Reduction in Digital Image Processing." Applied Mechanics and Materials 278-280 (January 2013): 1359–65. http://dx.doi.org/10.4028/www.scientific.net/amm.278-280.1359.

Full text

Abstract:

In order to reduce Gaussian and Salt & Pepper noises, a combination approach to noise reduction is presented by combining the median filter with the mean filter. The detail simulations show that the mode which the median filtering first and then the mean filtering is superior to that of the simply single filtering, or the mean filtering first and then the median filtering when the image obviously contain the Salt & Pepper noise. On the other hand, it is not necessarily the optimal scheme to use the mode which the mean filtering first and then the median filtering when the digital image

APA, Harvard, Vancouver, ISO, and other styles

10

Richardson, D. L., K. Kim, L. G. Seamon, et al. "Combination gemcitabine and cisplatin for recurrent ovarian cancer." Journal of Clinical Oncology 25, no. 18_suppl (2007): 16037. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.16037.

Full text

Abstract:

16037 Background: Recent evidence suggests gemcitabine combined with a platinum drug is active in recurrent ovarian cancer. In an effort to decrease dose-limiting myelosuppression associated with gemcitabine plus carboplatin, cisplatin can be substituted for carboplatin. Our objective is to describe a single institutional experience with day 1 and day 15 (D1/15) gemcitabine (1000 mg/m2) and cisplatin (30 mg/m2) for the treatment of recurrent ovarian cancer. Methods: A retrospective chart review was performed of all patients with recurrent epithelial ovarian, fallopian tube, and primary periton

APA, Harvard, Vancouver, ISO, and other styles

11

Manjunatha, B., Rishabh Singh Shyam, Dayananda Patil, et al. "Enhancing Agricultural Commodity Forecasting: A Median-Based Combination of Time Series Models." Journal of Experimental Agriculture International 46, no. 8 (2024): 954–65. http://dx.doi.org/10.9734/jeai/2024/v46i82782.

Full text

Abstract:

This study explores the efficacy of combining forecasts using the median operator to enhance forecasting performance. The traditional approach of assigning equal weights to individual models often struggles with extreme forecasts. A new method Simple Combination of Univariate Models (SCUM) is utilized, which uses the median operator to combine forecasts from four distinct time series models: Exponential Smoothing (ETS), Auto Regressive Integrated Moving Average (ARIMA), Dynamically Optimised Theta Model (DOTM), and Complex Exponential Smoothing (CES). This approach aims to mitigate the influen

APA, Harvard, Vancouver, ISO, and other styles

12

Sherman, Eric Jeffrey, Alan Loh Ho, Shrujal S. Baxi, et al. "Combination of dabrafenib (DAB)." Journal of Clinical Oncology 35, no. 15_suppl (2017): 6085. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.6085.

Full text

Abstract:

6085 Background: BRAFV600E mutations (BRAFm) are the most common mutations in thyroid cancer. BRAF inhibitors are active in BRAFm melanoma, but there is less activity noted in BRAFm thyroid cancer. Preclinically, BRAF inhibitors inhibit BRAFm thyroid cancers only transiently due to activation of HER2/HER3, driven by a neuregulin-dependent autocrine loop. The addition of LAP, a HER2/HER3 kinase inhibitor, sensitizes the cell to growth suppression by BRAF inhibitors (Cancer Discov 5(3):520, 2013). A phase I study evaluating the combination of DAB, a BRAF inhibitor, and LAP was initiated to evalu

APA, Harvard, Vancouver, ISO, and other styles

13

Orvain, Corentin, Suzanne Tavitian, Clemence Mediavilla, et al. "Outcome of Patients with Accelerated and Blast-Phase Myeloproliferative Neoplasms Ineligible for Intensive Chemotherapy or Allogeneic Hematopoietic Cell Transplantation Treated By Azacitidine Alone or in Combination - a FIM Study." Blood 144, Supplement 1 (2024): 3167. https://doi.org/10.1182/blood-2024-199055.

Full text

Abstract:

Background: Accelerated-phase (AP) or blast-phase (BP) myeloproliferative neoplasms (MPN) are associated with poor prognosis with better survival in patients who can proceed to allogeneic hematopoietic cell transplantation (HCT). However, some patients are ineligible for intensive therapy related to age, comorbidities, or clinical manifestations from disease; and non-curative therapies such as hypomethylating agents (HMA) can be considered. Some studies suggested that combining HMA with either ruxolitinib or venetoclax could be an interesting approach in this context. To assess the relationshi

APA, Harvard, Vancouver, ISO, and other styles

14

De Los Santos, Maria Ana Isabel C., Anne-Florence Blandin, Alejandra E. Aguilar, et al. "Abstract 6732: Identifying novel combination therapies for Ewing sarcoma." Cancer Research 83, no. 7_Supplement (2023): 6732. http://dx.doi.org/10.1158/1538-7445.am2023-6732.

Full text

Abstract:

Abstract Ewing sarcoma is the second most common pediatric bone cancer in children and young adults. The standard of care therapy consists of chemotherapy, surgery, and radiation. Despite therapeutic advances, metastatic and relapsed Ewing sarcoma have poor outcomes. This is partially because transcription factors, such as the Ewing sarcoma oncoprotein EWS-FLI1, are difficult targets for the development of small molecules. Novel synergistic combination treatments are needed, and drug repurposing efforts can fast track potential therapies into clinical trials. To identify synergistic anti-Ewing

APA, Harvard, Vancouver, ISO, and other styles

15

Schoen, Martin W., Ruth Douglas Etzioni, Eric Marshall Knoche, et al. "Treatment and survival of de novo metastatic prostate cancer in US veterans." Journal of Clinical Oncology 41, no. 6_suppl (2023): 87. http://dx.doi.org/10.1200/jco.2023.41.6_suppl.87.

Full text

Abstract:

87 Background: Combination therapies using the androgen deprivation therapy (ADT) backbone have revolutionized treatment of metastatic hormone sensitive prostate cancer (mHSPC). Combinations include ADT plus docetaxel (DOC) or the androgen receptor targeting agents (ARTAs) abiraterone (AA), enzalutamide (ENZ), apalutamide (APA), and darolutamide (DAR). This study evaluates the utilization of these therapies in de novo mHSPC in a cohort of veterans and assesses recent overall survival (OS) of these therapies. Methods: Veterans were identified from 2012-2021 in the Veterans Affairs Prostate Canc

APA, Harvard, Vancouver, ISO, and other styles

16

Kim, Ted, Clara Hao, Minggui Pan, Kristen N. Ganjoo, and Nam Q. Bui. "Gemcitabine Plus Docetaxel, Dacarbazine, Doxorubicin Combinations, or Doxorubicin Alone as First-Line Treatment for Advanced/Metastatic Leiomyosarcoma: A Retrospective Analysis at a Sarcoma Center." Diseases 13, no. 3 (2025): 79. https://doi.org/10.3390/diseases13030079.

Full text

Abstract:

Background/Objectives: Locally advanced and metastatic leiomyosarcoma (LMS) is an aggressive cancer with limited treatment options. This single-institution, retrospective study evaluated the efficacy of first-line chemotherapy regimens in patients with advanced or metastatic LMS treated at Stanford Medical Center. Methods: Seventy-four patients with unresectable or metastatic LMS were deemed eligible and treated with first-line chemotherapy regimens, including gemcitabine plus docetaxel, dacarbazine, doxorubicin combinations (with evofosfamide or ifosfamide), and doxorubicin monotherapy. Progr

APA, Harvard, Vancouver, ISO, and other styles

17

Dias, Joilson. "Educational system, income inequality and growth: the median voter's decision." Estudos Econômicos (São Paulo) 35, no. 1 (2005): 81–100. http://dx.doi.org/10.1590/s0101-41612005000100003.

Full text

Abstract:

I analyze a long run educational policy as a mechanism to close the income gap among low, median and high-income families. If the choice is made endogenous by the use of the median voter theorem, the results are as follow: i) public education system guarantees income convergence, however the income growth rate of the median voter is smaller; ii) the combination public and private (hybrid) educational system allows faster income growth rate, but income inequality is almost the natural outcome. The ending result is that the combination public and private system will prevail, since the income gro

APA, Harvard, Vancouver, ISO, and other styles

18

Abdul-Mutakabbir, Jacinda, Juwom Yim, Logan Nguyen, et al. "1542. The Evaluation of the In Vitro Synergy of Colistin in Combination with Meropenem and Tigecycline against 50 Multi-Drug-resistant Acinetobacter baumannii strains." Open Forum Infectious Diseases 6, Supplement_2 (2019): S562—S563. http://dx.doi.org/10.1093/ofid/ofz360.1406.

Full text

Abstract:

Abstract Background Acinetobacter baumannii possess inherent and acquired antibiotic resistance mechanisms that have rendered most antibiotics, including carbapenems, inactive. Colistin (COL) has risen as salvage therapy against these organisms due to its retained activity against A. baumannii. However, COL monotherapy is often met with suboptimal outcomes. Recently, combination therapy with COL and meropenem (MEM) or tigecycline (TGC) has been shown to be effective in eradicating multi-drug-resistant A. baumannii infections. The objective of this study was to further evaluate the efficacy of

APA, Harvard, Vancouver, ISO, and other styles

19

Puig, M. M., O. Pol, and W. Warner. "Interaction of Morphine and Clonidine on Gastrointestinal Transit in Mice." Anesthesiology 85, no. 6 (1996): 1403–12. http://dx.doi.org/10.1097/00000542-199612000-00022.

Full text

Abstract:

Background Combinations of drugs are frequently used to achieve effective analgesia while minimizing side effects. Although the analgesic effects of morphine and clonidine seem to be synergistic, few studies have investigated other effects. Their role in inhibiting gastrointestinal transit was evaluated using different methods of analysis. Methods Percentage inhibition of transit induced by morphine, clonidine, or their combination was measured in mice that had been given an intragastric charcoal meal. Dose-response curves were obtained for each drug individually; for morphine:clonidine at 1:3

APA, Harvard, Vancouver, ISO, and other styles

20

Milne, K. E. N., and I. M. Gould. "Combination Antimicrobial Susceptibility Testing of Multidrug-Resistant Stenotrophomonas maltophilia from Cystic Fibrosis Patients." Antimicrobial Agents and Chemotherapy 56, no. 8 (2012): 4071–77. http://dx.doi.org/10.1128/aac.00072-12.

Full text

Abstract:

ABSTRACTStenotrophomonas maltophiliais increasingly being isolated from the respiratory tract of individuals with cystic fibrosis, and, because of its multidrug-resistant nature, the selection of suitable treatment regimens can be problematical. Etest methodology was used to facilitate MIC and antimicrobial combination testing on 80 isolates ofS. maltophiliacultured from the respiratory tract of Scottish individuals with cystic fibrosis between 2001 and 2010. The overall rate of susceptibility for the 1,410 MIC tests was 23.1%, and resistance was 68.9%. The most active antimicrobials were mino

APA, Harvard, Vancouver, ISO, and other styles

21

Gasparini, Giampietro, Salvatore Turnolo, Giuseppe Toffoli, Renato Talamini, Alberto Vaglia, and Marco Benedetti. "Combination Antibiotic Treatment of Chemotherapy-Induced Neutropenia in Non-Leukemic Patients." Tumori Journal 75, no. 5 (1989): 443–48. http://dx.doi.org/10.1177/030089168907500508.

Full text

Abstract:

The use of more aggressive chemotherapies in the treatment of patients with some tumors has caused a higher frequency of neutropenia and subsequent serious infections. To verify the role in these patients of a combination therapy of amikacin (300 mg/m2 i.v. every 12 hours) plus ceftazidime (2 g/m2 i.v. every 8 hours) adminsitered as initial empiric treatment, followed in non-responsive cases by a second-line therapy with clindamycin (300 mg/m2 i.v. every 8 hours), we conducted a prospective study in 45 febrile episodes (temperature ≥38.5 °C) in neutropenic patients (neutrophils ≤500/ml). The p

APA, Harvard, Vancouver, ISO, and other styles

22

Linch, Mark D., Matthew W. Jenner, Sharon Dines, Faith E. Davies, and Gareth J. Morgan. "Thalidomide in Combination with Idarubicin, Dexamethasone and Etoposide (TIDE) Is an Effective Oral Combination in Heavily Pre-Treated Myeloma Patients." Blood 110, no. 11 (2007): 4841. http://dx.doi.org/10.1182/blood.v110.11.4841.4841.

Full text

Abstract:

Abstract Dexamethasone, thalidomide, etoposide and an antracycline have formed part of regimens such as DT-PACE which have demonstrated efficacy in previously treated patients with multiple myeloma. They are inpatient regimens which limit their usage in a palliative setting. We have designed an oral regimen incorporating these agents. The toxicity and efficacy data of this novel treatment are presented. Between October 2004 and May 2007 patients who had progressive myeloma or were intolerant of DT-PACE were treated with 100–200mg of thalidomide on days 1–21 and four days (D1–4) of 10mg/m2 idar

APA, Harvard, Vancouver, ISO, and other styles

23

Piliotis, Eugenia, Panayiota Govas, Kevin R. Imrie, et al. "Sezary Syndrome and Combination Immunomodulatory Therapy: Improving Clinical Outcomes." Blood 112, no. 11 (2008): 4957. http://dx.doi.org/10.1182/blood.v112.11.4957.4957.

Full text

Abstract:

Abstract Introduction: Sezary syndrome is a rare, aggressive and advanced stage of cutaneous T cell lymphoma where patients exhibit total body erythroderma and peripheral blood involvement. Patients can progress from preexisting mycoses fungoides or present de-novo. Historically median survival has been less than two years however with current combinations of skin directed and immunomodulatory therapy median survival has been documented up to 3–4 years, however randomized trials are lacking given the rarity of this disorder. We describe the outcomes 23 patients followed in our centre diagnosed

APA, Harvard, Vancouver, ISO, and other styles

24

Dimery, I. W., S. S. Legha, M. Shirinian, and W. K. Hong. "Fluorouracil, doxorubicin, cyclophosphamide, and cisplatin combination chemotherapy in advanced or recurrent salivary gland carcinoma." Journal of Clinical Oncology 8, no. 6 (1990): 1056–62. http://dx.doi.org/10.1200/jco.1990.8.6.1056.

Full text

Abstract:

Seventeen patients with recurrent or unresectable salivary gland carcinomas were treated with combination fluorouracil (5-FU), doxorubicin, cyclophosphamide, and cisplatin (FACP). Sixteen patients were assessable for response and toxicity. A total of 111 courses of chemotherapy were given, yielding one complete and seven partial responses, for an objective response rate of 50%. Two other patients had stable disease and two had a minor response. The median duration of objective response was 32 weeks (range, 4 to 72); median survival for the 16 patients was 72 weeks. Hematologic toxicity was sig

APA, Harvard, Vancouver, ISO, and other styles

25

Piccart-Gebhart, Martine J., Tomasz Burzykowski, Marc Buyse, et al. "Taxanes Alone or in Combination With Anthracyclines As First-Line Therapy of Patients With Metastatic Breast Cancer." Journal of Clinical Oncology 26, no. 12 (2008): 1980–86. http://dx.doi.org/10.1200/jco.2007.10.8399.

Full text

Abstract:

Purpose Taxanes (paclitaxel or docetaxel) have been sequenced or combined with anthracyclines (doxorubicin or epirubicin) for the first-line treatment of advanced breast cancer. This meta-analysis uses data from all relevant trials to detect any advantages of taxanes in terms of tumor response, progression-free survival (PFS), and survival. Patients and Methods Individual patient data were collected on eight randomized combination trials comparing anthracyclines + taxanes (+ cyclophosphamide in one trial) with anthracyclines + cyclophosphamide (+ fluorouracil in four trials), and on three sing

APA, Harvard, Vancouver, ISO, and other styles

26

Đặng, Thị Huyền Thương, та Ngọc Tài Trần. "Khảo sát tình hình điều trị thuốc cho người bệnh parkinson tại Bệnh viện Đại học Y dược TP. Hồ Chí Minh". Tạp chí thần kinh học Việt Nam, № 41 (15 липня 2024): 52–59. http://dx.doi.org/10.62511/vjn.41.2024.018.

Full text

Abstract:

Background: Parkinson's disease is one of the most common progressive neurodegenerative disorders. There's currently no cure for Parkinson's disease. Current therapies only help patients relieve the symptoms and improve their quality of life. Objectives: To determine the rate of drugs prescribed to treat Parkinson's disease motor symptoms, the rate of the types of drug combinations, and the frequency of drug-induced motor complications in Parkinson's disease patients. Methods: This cross-sectional study was conducted at the University Medical Center HCMC, Ho Chi Minh City. The patient was diag

APA, Harvard, Vancouver, ISO, and other styles

27

DeMare, Alexander M., Natalie C. Luehmann, Samer Kawak, et al. "Cost-Effective Approach to the Laparoscopic Appendectomy." American Surgeon 86, no. 6 (2020): 715–20. http://dx.doi.org/10.1177/0003134820923337.

Full text

Abstract:

Background Surgeons can help reduce health care spending by selecting affordable and efficient instruments. The laparoscopic appendectomy (LA) is commonly performed and can serve as a model for improving health care cost. Methods We retrospectively reviewed all adult patients who underwent LA for non-perforated appendicitis from March 2015 to November 2017. Our objective was to determine which combination of disposable instruments afforded the lowest total operative cost without compromising postoperative outcomes. Results In total, 1857 consecutive patients were reviewed from 2 hospitals. Aft

APA, Harvard, Vancouver, ISO, and other styles

28

Houillier, Caroline, Cecile Moluçon Chabrot, Marie-Pierre Moles-Moreau, et al. "Rituximab-Lenalidomide-Ibrutinib Combination for Relapsed/Refractory Primary CNS Lymphoma." Neurology 97, no. 13 (2021): 628–31. http://dx.doi.org/10.1212/wnl.0000000000012515.

Full text

Abstract:

Background and ObjectivesTo evaluate the efficacy and tolerance of the association rituximab-lenalidomide-ibrutinib (R2I) in relapsed/refractory (R/R) primary CNS lymphoma (PCNSL).MethodsR/R PCNSL patients treated with R2I were retrospectively selected and analyzed from the French LOC database.ResultsFourteen patients (median age: 63 years, median Karnofsky Performance Status: 75%) received R2I, administered after a median of 2 previous lines of chemotherapy, including autologous stem cell transplantation (ASCT) in 5 cases. The best response was complete response in 4/14 patients and partial r

APA, Harvard, Vancouver, ISO, and other styles

29

Ning, Yang-Min, James L. Gulley, Philip M. Arlen, et al. "Phase II Trial of Bevacizumab, Thalidomide, Docetaxel, and Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer." Journal of Clinical Oncology 28, no. 12 (2010): 2070–76. http://dx.doi.org/10.1200/jco.2009.25.4524.

Full text

Abstract:

Purpose We previously demonstrated that thalidomide appears to add to the activity of docetaxel in metastatic castration-resistant prostate cancer (CRPC). Phase II studies combining docetaxel with bevacizumab have had substantial antitumor activity. We hypothesized that the combination of docetaxel plus these antiangiogenic drugs with different targets would have substantial clinical activity. To explore safety and efficacy, this was tested in mice and in human patients. Patients and Methods Preclinical efficacy of the combination therapy was evaluated in PC3 xenograft mice. Sixty patients wit

APA, Harvard, Vancouver, ISO, and other styles

30

Jalonen, Harri, Jussi Kokkola, Valtteri Kaartemo, and Miika Vähämaa. "Sosiaalisen median hyödyntäminen nuorten palvelujen yhteiskehittämisessä." Hallinnon Tutkimus 40, no. 1 (2021): 5–22. http://dx.doi.org/10.37450/ht.107611.

Full text

Abstract:

Co-creation assumes an interactive and dynamic relationship where value is created at the nexus of interaction. Co-creating value is challenging with marginalized youths. In this article, social media is seen as an underutilized resource for developing services. This article approaches social media as a context from which it is possible to derive information that would otherwise be unattainable. Using data from a Finnish discussion board, this article answers the following question: How can the experiences of socially withdrawn youth shared on social media be used to enrich the knowledge base

APA, Harvard, Vancouver, ISO, and other styles

31

Kalita, Diana, and Pavel Lyakhov. "Moving Object Detection Based on a Combination of Kalman Filter and Median Filtering." Big Data and Cognitive Computing 6, no. 4 (2022): 142. http://dx.doi.org/10.3390/bdcc6040142.

Full text

Abstract:

The task of determining the distance from one object to another is one of the important tasks solved in robotics systems. Conventional algorithms rely on an iterative process of predicting distance estimates, which results in an increased computational burden. Algorithms used in robotic systems should require minimal time costs, as well as be resistant to the presence of noise. To solve these problems, the paper proposes an algorithm for Kalman combination filtering with a Goldschmidt divisor and a median filter. Software simulation showed an increase in the accuracy of predicting the estimate

APA, Harvard, Vancouver, ISO, and other styles

32

Avasare, Rupali S., Pietro A. Canetta, Andrew S. Bomback, et al. "Mycophenolate Mofetil in Combination with Steroids for Treatment of C3 Glomerulopathy." Clinical Journal of the American Society of Nephrology 13, no. 3 (2018): 406–13. http://dx.doi.org/10.2215/cjn.09080817.

Full text

Abstract:

Background and objectivesC3 glomerulopathy is a form of complement-mediated GN. Immunosuppressive therapy may be beneficial in the treatment of C3 glomerulopathy. Mycophenolate mofetil is an attractive treatment option given its role in the treatment of other complement-mediated diseases and the results of the Spanish Group for the Study of Glomerular Diseases C3 Study. Here, we study the outcomes of patients with C3 glomerulopathy treated with steroids and mycophenolate mofetil.Design, setting, participants, & measurementsWe conducted a retrospective chart review of patients in the C3 glo

APA, Harvard, Vancouver, ISO, and other styles

33

Zubkova, Olga A., Larissa S. Agapova, Armen A. Ovsepyan, et al. "Synergy of optimized administration sequence and timing of active DC immunotherapy with a PD1 checkpoint inhibitor in a mouse model of renal cell carcinoma." Journal of Clinical Oncology 36, no. 5_suppl (2018): 31. http://dx.doi.org/10.1200/jco.2018.36.5_suppl.31.

Full text

Abstract:

31 Background: AGS-003 is an immunotherapy consisting of autologous dendritic cells electroporated with amplified total tumor RNA plus synthetic CD40L RNA and is currently being tested in combination with standard of care to extend survival of newly diagnosed metastatic renal cell carcinoma (RCC) patients in the Phase 3 ADAPT clinical trial. We set out to establish a model system based on the Renca mouse model to more thoroughly study the AGS-003 mechanism of action and identify optimal combination therapies, including with a PD1 checkpoint inhibitor (aPD1 CPI). Methods: Mouse DC precursors we

APA, Harvard, Vancouver, ISO, and other styles

34

Dorff, Tanya B., Debra Hawes, Denice D. Tsao-Wei, et al. "A combination herbal supplement for biochemically recurrent prostate cancer." Journal of Clinical Oncology 30, no. 5_suppl (2012): 24. http://dx.doi.org/10.1200/jco.2012.30.5_suppl.24.

Full text

Abstract:

24 Background: After curative local therapy, thousands of men will have rising PSA as an early indicator of recurrent prostate cancer. For them, no standard of care exists, and concern over serious side effects of androgen deprivation (ADT) makes delaying ADT common. We tested Prostate Health Cocktail (PHC), which contains vitamins D & E, saw palmetto, lycopene, green tea and soy extracts, in this population, to see whether it could induce PSA declines. Methods: Eligible men had rising PSA with doubling time (DT) 3-36 months, with no evidence of metastases on CT and bone scans. After IRB a

APA, Harvard, Vancouver, ISO, and other styles

35

Rauthan, Amit, Poonam Patil, Nitin Yashas Murthy, et al. "Combination of immunotherapy and tyrosine kinase inhibitor in first-line metastatic renal cell carcinoma: A real-world Indian experience." Journal of Clinical Oncology 39, no. 15_suppl (2021): e16576-e16576. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.e16576.

Full text

Abstract:

e16576 Background: Immuno-oncology (IO) agents in combination with oral tyrosine kinase inhibitors (TKIs) has become a standard first line therapy in metastatic renal cell carcinoma (mRCC) patients. Various combinations such as pembrolizumab + axitinib, avelumab + axitinib, nivolumab + cabozantinib and pembrolizumab + lenvatinib have all shown better results than sunitinib. There is very limited data about this from India. Methods: This is a single center, retrospective study of mRCC patients, who received first line treatment was nivolumab or pembrolizumab with axitinib or lenvatinib. The end

APA, Harvard, Vancouver, ISO, and other styles

36

Wang, Daqing, Melissa Precopio, Michael J. Reardon, et al. "IMO-4200, a Novel TLR7 and TLR8 Dual Agonist, Enhances Antitumor Effect of Ofatumumab, Rituximab and Cytotoxics in Preclinical Models of Hematological Malignancies,." Blood 118, no. 21 (2011): 3724. http://dx.doi.org/10.1182/blood.v118.21.3724.3724.

Full text

Abstract:

Abstract Abstract 3724 Background Toll-like receptors (TLR) are ideal targets for combination therapy of hematological malignancies as they modulate immune responses and can influence the tumor microenvironment through cytokine and chemokine induction. TLR-targeted agents have potential to treat hematological tumors by regulating the innate and acquired immune responses to cancer cells. We have previously shown that IMO-4200, a TLR7 and TLR8 dual agonist enhanced the antibody-dependent cell cytotoxicity (ADCC) of rituximab on Raji and Granta human lymphoma cell lines in vitro. Furthermore, we

APA, Harvard, Vancouver, ISO, and other styles

37

Abbas, R., N. Ibrahim, M. Elawad, F. Al-Mudahka, H. Abdelrhman, and A. K. Akobeng. "P617 Dual biologic therapy in pediatric Inflammatory Bowel Disease." Journal of Crohn's and Colitis 17, Supplement_1 (2023): i747. http://dx.doi.org/10.1093/ecco-jcc/jjac190.0747.

Full text

Abstract:

Abstract Background There is paucity of data on the effectiveness of combination biologic agents as an option for children with refractory inflammatory bowel disease (IBD) that is inadequately controlled by biologic monotherapy. The aims of this study were to determine the effectiveness and safety of combination biologic use in pediatrics IBD. Methods A retrospective cohort study of children with IBD seen at Sidra Medicine and who received combination biologic therapy from October 2018 to April 2022. The diagnosis of IBD was established according to the revised Porto criteria. Children with IB

APA, Harvard, Vancouver, ISO, and other styles

38

Imai, Hiroo, Hidekazu Shirota, Akira Okita, et al. "Efficacy and Safety of Carboplatin and Etoposide Combination Chemotherapy for Extrapulmonary Neuroendocrine Carcinoma: A Retrospective Case Series." Chemotherapy 61, no. 3 (2015): 111–16. http://dx.doi.org/10.1159/000441551.

Full text

Abstract:

Background: Neuroendocrine carcinoma (NEC) is a rare tumor type, and a standard therapy for NEC has not yet been established. From 2008 to 2013, carboplatin-etoposide combination therapy has been used to treat almost all NEC patients in our department, and the objective of the present study was to investigate the therapeutic effects of carboplatin-etoposide combination therapy in NEC. Methods: This retrospective study was conducted based on medical records from 2008 to 2013. Eligible patients had been pathologically diagnosed with NEC and had received a carboplatin-etoposide combination as fir

APA, Harvard, Vancouver, ISO, and other styles

39

Saito, Jumpei, Miho Yamaguchi, Seiichi Shimizu, et al. "Investigation on the Usefulness of Sulfamethoxazole Trimethoprim Combination Small Tablets in Pediatric Pharmacotherapy: A Single Center Observational Study Using a Questionnaire." Children 9, no. 10 (2022): 1598. http://dx.doi.org/10.3390/children9101598.

Full text

Abstract:

Sulfamethoxazole trimethoprim (ST) combinations are used to prevent infection in immunocompromised patients. In pediatric patients, conventional ST combination tablets (cTab) are large and granules are not preferred due to their rough and bitter taste in the mouth. Since a new formulation of smaller tablets (sTab, 1 cTab = 1-gram granules = 4 sTab) was approved, a study regarding the usability of sTab in pediatric patients was conducted. Children who started taking sTab of the ST combination at our hospital between August 2021 and August 2022 were included. Using an anonymous questionnaire, th

APA, Harvard, Vancouver, ISO, and other styles

40

Lingohr-Smith, Melissa, Chelsea Deitelzweig, Grace Lin, and Jay Lin. "558 Programmed death (PD)-1 and PD-ligand-1 inhibitors in the treatment of non-small cell lung cancer: a systematic review of their efficacy and safety." Journal for ImmunoTherapy of Cancer 8, Suppl 3 (2020): A592. http://dx.doi.org/10.1136/jitc-2020-sitc2020.0558.

Full text

Abstract:

BackgroundTreatment advances have been made in non-small cell lung cancer (NSCLC) with the development and approval of programmed death (PD)-1 and PD-ligand 1 (PD-L1) inhibitors. PD-1 and PD-L1 inhibitors may be used as monotherapies or in combination with other agents and have been shown to improve NSCLC patient outcomes in clinical trials. We conducted a systematic search to compare the efficacy and safety of PD-1/PD-L1 inhibitors in the treatment of NSCLC.MethodsA systematic literature search of PubMed was conducted to identify phase III clinical trials in which the efficacy of PD-1/PD-L1 i

APA, Harvard, Vancouver, ISO, and other styles

41

Lekkas, C., B. S. Latief, and J. E. M. Corputty. "Median Cleft of the Lower Lip Associated with Lip Pits and Cleft of the Lip and Palate." Cleft Palate-Craniofacial Journal 35, no. 3 (1998): 269–71. http://dx.doi.org/10.1597/1545-1569_1998_035_0269_mcotll_2.3.co_2.

Full text

Abstract:

Objective In this case report, we present an unusual combination of three congenital malformations: median cleft of the lower lip, lip pits, and unilateral cleft of the lip and palate without familial occurrence. Conclusions From an etiological point of view, this combination of malformations could have happened during the late embryogenic period. Why this combination is uncommon is not known.

APA, Harvard, Vancouver, ISO, and other styles

42

Frenel, Jean-Sebastien, Jean Zeghondy, Catherine Guérin-Charbonnel, et al. "Tucatinib Combination Treatment After Trastuzumab-Deruxtecan in Patients With ERBB2-Positive Metastatic Breast Cancer." JAMA Network Open 7, no. 4 (2024): e244435. http://dx.doi.org/10.1001/jamanetworkopen.2024.4435.

Full text

Abstract:

ImportanceLittle is known regarding the outcomes associated with tucatinib combined with trastuzumab and capecitabine (TTC) after trastuzumab-deruxtecan exposure among patients with ERBB2 (previously HER2)-positive metastatic breast cancer (MBC).ObjectiveTo investigate outcomes following TTC treatment in patients with ERBB2-positive MBC who had previously received trastuzumab-deruxtecan.Design, Setting, and ParticipantsThis cohort study included all patients with MBC who were treated in 12 French comprehensive cancer centers between August 1, 2020, and December 31, 2022.ExposureTucatinib combi

APA, Harvard, Vancouver, ISO, and other styles

43

Mazzer, M., E. Zanon, L. Foltran, et al. "Second-line pemetrexed–oxaliplatin combination for advanced pancreatic adenocarcinoma." Journal of Clinical Oncology 27, no. 15_suppl (2009): e15597-e15597. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.e15597.

Full text

Abstract:

e15597 Background: Few regimens showed efficacy in advanced pancreatic cancer patients (pts) who had failed a first-line gemcitabine-based therapy. However, there is growing evidence suggesting that second-line treatment may provide further disease control in selected pts. Both pemetrexed and oxaliplatin demonstrated activity in this setting, and their combination resulted safe and tolerable.Methods: Pancreatic cancer pts with advanced disease, PS>60, age>18 years, who progressed after a gemcitabine-based therapy were enrolled in a phase II trial, and treated with pemetrexed 500 mg/mq fo

APA, Harvard, Vancouver, ISO, and other styles

44

Menefee, M., M. Edgerly, M. Velarde, K. Herbert, and A. T. Fojo. "The efficacy of combination chemotherapy with cisplatin and gemcitabine in patients with advanced adrenal cortical carcinoma (ACC)." Journal of Clinical Oncology 24, no. 18_suppl (2006): 12033. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.12033.

Full text

Abstract:

12033 Background: ACC is a rare, but highly lethal disease for which more effective systemic therapies are needed. Prior studies have concluded that cisplatin and doxorubicin have single agent activity and that combinations of these and other agents, most notably etoposide, may have additive or synergistic effects. However, the majority of responses are neither complete nor durable. Anecdotal evidence of activity by gemcitabine in patients with ACC motivated the present analysis, designed to assess the efficacy of cisplatin and gemcitabine in combination in patients with metastatic ACC. Method

APA, Harvard, Vancouver, ISO, and other styles

45

Fadrus, Pavel, Vaclav Vybihal, Vilem Juran, et al. "MMOD-15 SURGICAL RESECTION AND STEREOTACTIC RADIOSURGERY IN COMBINATION FOR LOCAL THERAPY OF BRAIN METASTASES." Neuro-Oncology Advances 6, Supplement_1 (2024): i19. http://dx.doi.org/10.1093/noajnl/vdae090.059.

Full text

Abstract:

Abstract OBJECTIVES Complex local treatment of BM combining surgical resection and radiosurgery provides the possibility of adequate local control while maintaining a satisfactory quality of life. METHODS Patients after surgical resection and postoperative radiotherapy treated between 2007-2023 were evaluated. Local control was assessed separately at the site of the operated MM (localPFS) and separately in other parts of the brain (distalPFS). RESULTS A total of 158 patients were enrolled (70 with WBRT), 56% were women, the median age was 61 years, the median performance status Karnofsky 78%.

APA, Harvard, Vancouver, ISO, and other styles

46

Naval, Daver, Jorge E. Cortes, Elias Jabbour, et al. "Ruxolitinib and Lenalidomide As a Combination Therapy for Patients with Myelofibrosis." Blood 124, no. 21 (2014): 1831. http://dx.doi.org/10.1182/blood.v124.21.1831.1831.

Full text

Abstract:

Abstract Background: Ruxolitinib (RUX) is a potent and selective inhibitor of the JAK/STAT pathway that significantly abrogates splenomegaly and constitutional symptoms in patients (pts) with myelofibrosis (MF). Lenalidomide (LEN) is a second-generation immunomodulatory agent that may improve MF-associated anemia and thrombocytopenia. RUX and LEN possess complimentary efficacy profiles. Aim:Our single-center phase II open-labeled study was conducted to determine the efficacy and safety of the combination of RUX with LEN in pts with MF. Objective improvements were defined using International Wo

APA, Harvard, Vancouver, ISO, and other styles

47

Leonard, R. C., M. A. Cornbleet, S. B. Kaye, et al. "Mitoxantrone versus doxorubicin in combination chemotherapy for advanced carcinoma of the breast." Journal of Clinical Oncology 5, no. 7 (1987): 1056–63. http://dx.doi.org/10.1200/jco.1987.5.7.1056.

Full text

Abstract:

One hundred fifteen patients with metastatic carcinoma of the breast were treated in a randomized trial of mitoxantrone (Novantrone, Lederle Laboratories, Pearl River, NY) combined with vincristine and prednisolone (VMP) or doxorubicin (Adriamycin, Adria Laboratories, Columbus, OH) combined with vincristine and prednisolone (VAP). In 100 evaluable patients, the objective response rates were 35% for VMP and 61% for VAP, the complete response rates being 6% and 13%, respectively. In responding patients, median time to progression was 6.2 months for VMP and 7.9 months for VAP. The median survival

APA, Harvard, Vancouver, ISO, and other styles

48

Nakabori, Tasuku, Sena Higashi, Yutaro Abe, et al. "Safety and Feasibility of Combining On-Demand Selective Locoregional Treatment with First-Line Atezolizumab Plus Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma." Current Oncology 31, no. 3 (2024): 1543–55. http://dx.doi.org/10.3390/curroncol31030117.

Full text

Abstract:

Various locoregional treatments for localized hepatocellular carcinoma (HCC) have been developed. This retrospective study investigated the safety and feasibility of combining on-demand selective locoregional treatment for residual lesions after tumor shrinkage (complete response [CR] oriented) or for solitary or few drug-resistant lesions (progressive disease (PD) salvage) with first-line atezolizumab plus bevacizumab (atezo/bev) for unresectable HCC. Twenty-nine patients with unresectable HCC were included. Fourteen locoregional treatments were performed (CR oriented, 7; PD salvage, 7) in te

APA, Harvard, Vancouver, ISO, and other styles

49

Yildiz, Ramazan, Suleyman Buyukberber, Dogan Koca, et al. "The efficacy and safety of first-line and salvage therapies with bevacizumab combination chemotherapy regimens in metastatic colorectal cancer: A retrospective ASMO experience." Journal of Clinical Oncology 31, no. 15_suppl (2013): e14705-e14705. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.e14705.

Full text

Abstract:

e14705 Background: The addition of bevacizumab to chemotherapy significantly shows survival advantage in metastatic colorectal cancer (mCRC), but with limited data about irinotecan combination in salvage therapy. Efficacy and toxicity of bevacizumab combination regimens were assessed in first-line and salvage therapies. Methods: Total of 1011 (659 in first-line and 352 in salvage) patients were retrospectively evaluated. Results: In first-line therapy, the ORR was 36.4%. Median PFS was 7 months for FOLFIRI, 6 months for IFL and 6 months for other chemotherapy regimens with a median overall PFS

APA, Harvard, Vancouver, ISO, and other styles

50

Bobin, Arthur, Ennebet Soufyane, Stephanie Guidez, et al. "The Combination of Isatuximab with Pomalidomide and Dexamethasone in Second Line Relapse and Refractory Multiple Myeloma." Blood 144, Supplement 1 (2024): 7041. https://doi.org/10.1182/blood-2024-210687.

Full text

Abstract:

Introduction: The most impressive data obtained from CD38 targeting immunotherapies-based regimens were observed when used as early as possible in the MM disease course, in second line if not offered in line 1. CD38 targeting immunotherapies, Isatuximab and Daratumumab, are approved in the relapse-refractory Multiple Myeloma (RRMM) setting in triplet-based combinations with pomalidomide (P) and dexamethasone (IsaPd and DPd), however with very limited data in line 2 with IsaPd. Methods: We conducted a multicenter review study of the patients with second line RRMM treated with CD38 targeting imm

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!